Hextend (6% hetastarch in lactated electrolyte injection) is a
plasma volume expander indicated in the treatment of low levels of blood plasma (hypovolemia) when plasma volume expansion is desired
. Hextend is not a substitute for blood or plasma.
Is hextend a blood product?
HEXTEND (6% Hetastarch in Lactated Electrolyte Injection) is indicated in the treatment of hypovolemia when plasma volume expansion is desired. It is
not a substitute for blood or
plasma.
When do you give hespan?
- HESPAN
®
is indicated in the treatment of hypovolemia when plasma volume expansion is desired. … - The serious adverse events reported in clinical trials are increased mortality and renal replacement therapy renal in critically ill patients.
How do you give hespan?
How is Hespan given? Hespan is
injected into a vein through an IV
. A healthcare provider will give you this injection.
Can you give TXA with Hextend?
ABSTRACT Introduction: The current Tactical Combat Casualty Care Guidelines recommend tranexamic acid (TXA) administration for casualties in whom massive blood transfusion is anticipated. However, despite Hextend being the recommended resuscitation fluid, the
guidelines recommend against
using TXA with Hextend.
What is Plasmalyte used for?
PL 148, also known as Plasma-Lyte A, is a sterile isotonic non-pyrogenic IV crystalloid solution used
in clinical medicine to provide water, electrolytes and calories to patients
.
Is hextend a crystalloid?
Tactical Field Care and TACEVAC Care
plasma and RBCs in 1:1 ratio; plasma or RBCs alone; Hextend; and crystalloid (lactated Ringers or Plasma-Lyte A).
How much Hetastarch is normally used for a patient?
Typically, hetastarch products are given at
doses up to 20 mL/kg/day
. In critical patients, however, the benefits of the product may outweigh the risks of higher doses. For instance, a dose up to 40 to 50 mL/kg/day of hetastarch may be needed to obtain the desired effects.
What IV fluids are volume expanders?
The most commonly used crystalloid fluid is
normal saline
, a solution of sodium chloride at 0.9% concentration, which is close to the concentration in the blood (isotonic). Ringer's lactate or Ringer's acetate is another isotonic solution often used for large-volume fluid replacement.
What is Plasmanate?
Treatment of Shock
— Plasmanate is indicated in the treatment of shock due to burns, crushing injuries, abdominal emergencies, and any other cause where there is a predominant loss of plasma fluids and not red blood cells. It is also effective in the emergency treatment of shock due to hemorrhage.
What is VetStarch?
VetStarch is
a plasma volume substitute indicated for the treatment and prophylaxis of hypovolemia
. DOSAGE AND ADMINISTRATION: Administer by intravenous infusion only.
What is the half life of Hetastarch?
Metabolism proceeds at such a rate that volume expansion is seen for 24-36 hours with a maximum effect (100-172 percent of the infused volume) occurring shortly after infusion. Ninety percent of the dose is eliminated with a half-life of
about 17 days
.
Is Hetastarch a brand name?
Hetastarch is used to treat low blood volume (hypovolemia) and to remove leukocytes from drawn blood (leukapheresis). Hetastarch is available under the following different brand names:
Hespan and Hextend
.
Can you IV push TXA?
Intravenous TXA for hemorrhagic shock, including postpartum hemorrhage and trauma patients. Adult dose:
one gram bolus in 100 mL of normal saline over 10 minutes
(slow intravenous push). Rapid infusion may cause hypotension. May repeat a 1 gram dose over the next 8 hours, but do not exceed a total of 2 grams.
How do you administer TXA?
1 gram administered
over 10 minutes
for the initial dose. Mix 1 gram (10 ml) in 50 ml of NS and infuse via IV pump over 10 minutes. Set infusion pump rate @ 360 ml/hr. Maintenance Infusion- Mix 1 gram (10 ml) in 100 ml of NS and infuse over 8 hours.
Is TXA compatible with LR?
TXA is diluted in at least 100 mL of normal saline or lactated Ringer's solution and given over 10 minutes. Hextend
is not recommended as a carrier fluid
for TXA because of the concern for drug incompatibility.
